Skip to main content
Article thumbnail
Location of Repository

Anemia in children with chronic kidney disease

By Susan M. Koshy and Denis F. Geary


Anemia is a common feature of chronic kidney disease, but the management of anemia in children is complex. Erythropoietin and supplemental iron are used to maintain hemoglobin levels. The National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) clinical practice guidelines for the management of anemia specifically in children were recently published. Pediatric nephrologists are encouraged to use current clinical practice guidelines and best evidence in conjunction with their clinical experience to optimally manage patients with anemia

Topics: Educational Feature
Publisher: Springer-Verlag
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1999). An indistinct balance: the safety and efficacy of parenteral iron therapy.
  2. (2004). Anemia and health-related quality of life in adolescents with chronic kidney disease.
  3. (2003). Anemia in pediatric hemodialysis patients: results from the
  4. (2003). Anemia management and the delay of chronic renal failure progression.
  5. (1995). Balance between pro-inflammatory cytokines and their specific inhibitors in patients on dialysis.
  6. (1987). Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having hemodialysis.
  7. (2002). Biochemical markers and hematologic indices in the diagnosis of functional iron deficiency.
  8. Calcium containing binders
  9. (1994). Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia? Arch Dis Child 71:119–122
  10. (2004). Clinical experience with Darbepoetin Alfa (NESP) in children undergoing hemodialysis.
  11. (1985). Cloning and expression of the human erythropoietin gene.
  12. (2006). Consquences of long-term proton pump blockage: insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98:4–19
  13. (1987). Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial.
  14. (2005). Darbepoetin Alfa (Aranesp) in children with chronic renal failure.
  15. (1999). Diagnosis of iron deficiency in end stage renal disease.
  16. (1999). Disorders of iron metabolism.
  17. (1996). Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients?
  18. (2005). Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease.
  19. (1986). Effective human erythropoietin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis.
  20. (2005). Epoetin induced autoimmune pure red cell aplasia.
  21. (1999). Erythrocyte zinc protoporphyrin.
  22. (1984). Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency.
  23. (1991). Erythropoietin in anemia of renal failure in sickle cell disease.
  24. (2002). Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines.
  25. (1990). Erythropoietin, aluminium, and anaemia in patients on hemodialysis.
  26. (2003). Erythropoietin: physiology and pharmacology update.
  27. Evens AM (2005) Long term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin; a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project.
  28. (2005). Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the prompt study.
  29. (2005). Ferrlecit Pediatric Study Group. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
  30. (2002). Heatherington A
  31. (2005). Hematological and iron-related analytes – reference data for persons aged 1 year and over: United States,
  32. (1977). Hemolysis and blood loss in children with chronic renal failure.
  33. (1994). Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis.
  34. (1993). Influence of thalassemia on the response to recombinant human erythropoietin in dialysis patients.
  35. (2004). Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study. Pediatr Nephrol
  36. (1992). Iordache A
  37. (1997). Iron management in end-stage renal disease.
  38. (2004). Iron therapy in pediatric hemodialysis patients: a meta-analysis. Pediatr Nephrol 19:662–
  39. (2004). Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol
  40. (1998). Iron treatment: impact of safety issues.
  41. (1985). Isolation and characterization of genomic cDNA clones of human erythropoietin.
  42. (2006). Kidney Foundation
  43. (1999). Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin.
  44. (2001). Maintenance intravenous iron therapy in pediatric hemodialysis patients.
  45. (1996). Methods hematology: basic methodology in clinical diagnosis and management by laboratory methods, 19th edn.
  46. (2003). Morbidity and mortality in children with anemia at initiation of dialysis.
  47. (2008). Myelofibrosis Pediatr Nephrol
  48. (1996). Myelofibrosis secondary to renal osteodystrophy.
  49. (2000). Nelson textbook of pediatrics, 16th edn.
  50. (1993). Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia.
  51. (1999). Normal iron physiology. Semin Dialysis 12:219–223 Pediatr Nephrol
  52. (2001). Novel erythropoesis-stimulating protein for treatment of anemia in chronic renal insufficiency.
  53. (1990). One year’s experience with recombinant erythropoietin in children undergoing continuous ambulatory or cycling peritoneal dialysis.
  54. (2000). Oral L-carnitine does not decrease erythropoietin requirement in pediatric dialysis.
  55. (2004). Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease.
  56. (2004). Pediatric Renal Transplant Cooperative Study Registry Report
  57. (1999). Pharmacokinetics of novel erythropoesis-stimulating protein compared with epoetin alfa in dialysis patients.
  58. (2004). Prevalence of anemia in erythropoietin-treated pediatric as compared to adult chronic dialysis patients.
  59. (2006). Prevalence of complications in children with chronic kidney disease according to KDOQI.
  60. (2002). Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin.
  61. (2002). Randomized control trial of Darbepoetin Alfa for the treatment of anemia in hemodialysis patients.
  62. (2003). Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients.
  63. (2004). Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.
  64. (2004). Red blood cell survival in chronic renal failure.
  65. (1995). Resistance to erythro- poietin in ironoverloaded haemodialysis patients can be overcome by ascorbic acid administration.
  66. (2005). Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis.
  67. (2002). Serum soluble transferrin receptor reflects erythropoiesis but not iron availability in erythropoietin-treated chronic hemodialysis patients.
  68. (2000). Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors.
  69. (1999). Sodium ferric gluconate complex in sucrose: saferintravenous iron therapy than iron dextrans.
  70. (1982). Spurious elevation of electronically determined mean corpuscular volume and hematocrit caused by hyperglycemia.
  71. (2001). Suspected iron dextran-related adverse drug events in hemodialysis patients.
  72. (2006). The definition of anemia: what is the lower limit of normal of the blood hemoglobin concentration.
  73. (1998). The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
  74. (1996). The effects of recombinant human erythropoietin on growth and nutritional status.
  75. (1992). The molecular mechanism of molecular erythropoietin production.
  76. (1996). The safety of intravenous iron dextran in hemodialysis patients.
  77. (2006). The use of Darbepoetin in infants with chronic renal impairment.
  78. (1989). Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.
  79. (1989). Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cycling peritoneal dialysis.
  80. (2001). Why is erythropoietin made in the kidney? The kidney functions as a critmeter.
  81. (1999). Wintrobe’s clinical hematology, 10th edn. Lippincott Williams and Wilkins,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.